In vivo imaging platform for tracking immunotherapeutic cells
In vivo imaging platform for tracking immunotherapeutic cells
复制标题
DOI：
10.1038/nbt1121
复制
发表时间：
2005-08-01
影响因子：
46.9
通讯作者：
Morel, PA
中科院分区：
文献类型：
--
作者：
Ahrens, ET;Flores, R;Morel, PA
细胞疗法在疾病的治疗方面显示出巨大的前景，但很少有非侵入性技术用于监测给药后的细胞。在这里，我们提出了一种磁共振成像（MRI）技术，使用全氟聚醚（PFPE）剂在体内跟踪细胞。氟MRI选择性地只对标记的细胞成像，而“常规”H-1图像将细胞置于其解剖环境中。我们标记的表型定义的树突状细胞（DC）与PFPE离体和观察到有效的细胞内摄取的PFPE与DC功能的影响不大。我们将标记的DC注射到小鼠的组织中或静脉内，然后使用F-19 MRI在体内追踪细胞。虽然我们关注的是DC，它正在被开发为癌症和自身免疫性疾病的免疫治疗药物，但这项技术应该有助于监测体内广泛的细胞类型。
Cellular therapeutics show great promise for the treatment of disease, but few noninvasive techniques exist for monitoring the cells after administration. Here we present a magnetic resonance imaging (MRI) technology that uses perfluoropolyether (PFPE) agents to track cells in vivo. Fluorine MRI selectively images only the labeled cells, and a 'conventional' H-1 image places the cells in their anatomical context. We labeled phenotypically defined dendritic cells (DCs) with PFPE ex vivo and observed efficient intracellular uptake of the PFPE with little effect on DC function. We injected labeled DCs into tissue or intravenously in mice and then tracked the cells in vivo using F-19 MRI. Although we focused on DCs, which are being developed as immunotherapeutics for cancer and autoimmune diseases, this technology should be useful for monitoring a wide range of cell types in vivo.